Precision Medicine Market Size, Share, Market Types, Business Providers Forecast to 2027
As per the research reports by MRFR, the global precision
medicine market is likely to record a healthy CAGR of over 12.50% during the
review timeframe. The report projects that the market is anticipated to attain
a size of over USD 126.14 billion by the end of 2025.
Precision medicine, also called personalized medicines, has
been gaining traction worldwide as they allow the intrusion of patients in
taking personal healthcare and offer more targeted therapies for patients that
will offer lucrative opportunities over the review timeframe. The global Precision
Medicine Market Size has witnessed massive growth due to advanced
technological developments, more targeted therapies to the individuals,
increasing prevalence of various genetic diseases, and the launch of numerous
big data healthcare companies. However, the increased costs of diagnosis
and strict regulations and standards can restrict the market's growth over the
coming years.
Competitive Analysis
The global market for precision medicine has a strong and
competitive landscape. The list of leading players in the precision medicine
market includes companies such as Intomics A/S, GE Healthcare, ASURAGEN, Inc.,
ABBOTT LABORATORIES, Medtronic, Novartis, BIOBASE GmbH (Subsidiary), LABORATORY
CORPORATION OF AMERICA HOLDINGS, CETICS Healthcare Technologies GmbH,
bioMérieux SA, Teva Pharmaceutical Industries Ltd., Sanofi Pharma, Takeda
Pharmaceutical Company Limited, Randox Laboratories Ltd, Johnson & Johnson,
Cepheid Inc., InnVentis, Intel Corporation, AB-Biotics SA, Caris Life Sciences,
Quest Diagnostics Inc., Glaxosmithkline Plc (GSK), IBM, Molecular Health GmbH,
and Precision for Medicine, HealthCore, Inc., Roche Holding AG-Br, Pfizer Inc,
Qiagen, Almac Group, Ltd., and many others.
Segment Analysis
The global precision medicine market is divided into
segments based on submarkets, therapeutics, region, and ecosystem players.
- Based on submarkets,
the market is split into molecular diagnostics, targeted therapeutics,
pharmacogenomics or PGX, companion diagnostics, biomarker-based
tests, and many more.
- Based on therapeutics,
the precision medicines market is split into infectious disease, central
nervous system, cardiovascular disease or CVD, cancer or oncology,
and others.
- Based on the ecosystem
players, the precision medicine market is divided into pharmaceuticals
and biotechnology companies, healthcare IT specialists or big data
companies, clinical laboratories, diagnostics companies, and many more.
Regional Analysis
The global market for precision medicines is studied across
five major regions: North America, South America, Europe, Asia-Pacific, and the
Middle East & Africa.
As per the MRFR report, the North American region will
likely dominate the precision medicines market globally over the review
timeframe. The regional market's growth is attributed to the advanced gene
mapping technologies and growing demand for personalized medicine.
The European regional market for precision medicines is
likely to secure the second position globally over the coming years owing to
the well-developed healthcare infrastructure and consistent technological
advancements.
The growth of the precision medicines market for the
Asia-Pacific region is being driven by the better healthcare infrastructure and
increased disposable income.
Recent Developments
- January 2022—Caris Life
Sciences®, the prominent company in molecular science and technology
proactive in the development and delivery of innovative solutions to
transform healthcare, and HotSpot Therapeutics, Inc., a biotechnology firm
pioneering the discovery and development of high-quality allosteric
therapies focusing on regulatory sites on proteins referred to as
"natural hotspots," have announced a planned collaboration to
develop precision
medicine methods for HotSpot's emerging product portfolio. The
partnership will primarily target two therapeutic programs.
- January 2022- a company
translating genetic insights into new precision medicines, Maze Therapeutics,
has announced a USD 190 million investment led by Matrix Capital
Management with contribution from General Catalyst, Foresite Capital,
Casdin Capital, a16z Bio+Health, NS Investments, Moore Strategic Ventures,
City Hill Ventures, Terra Magnum Capital Partners, Driehaus Capital
Management, Woodline Partners, and several others. Maze was introduced in
2019 and has generated two joint ventures and nine programs since then.
- January 2022 – a precision
medicine firm looking for unlocking the proteome to advance innovations
against otherwise undruggable disease-causing targets, Frontier Medicines
Corporation has announced the first target to develop a small molecule
inhibitor is developing into the lead production stage under the firm's
global partnership with AbbVie. The worldwide partnership was founded in
December 2020 to discover, develop, and commercialize a pipeline of the
latest small molecule therapeutics against some high-interest,
difficult-to-drug protein targets.
Related Report: U.S.
Direct Anterior Approach Market Research Report –Global Forecast to 2027
Flow
Cytometry Market Research Report – Forecast to 2027
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment